Objective: To evaluate the efficacy and safety of Wenxin granule combined with Western medicine in the treatment of atrial fibrillation. Methods Six mainstream Chinese and English databases including Pubmed,Embase,Cochrane,Chinese biological literature database,CNKI,and Wanfang were searched and collected for systematic reviews on the treatment of atrial fibrillation by using the method of overview of systematic review. Based on the methodological quality appraisal tool AMSTAR 2 and reporting checklist PRISMA statement, the methodological quality and the reporting quality of the included systematic reviews were assessed respectively. A qualitative analysis was conducted to evaluate the efficacy and safety of Wenxin granule combined with Western medicine for atrial fibrillation on the cardioversion rate, the recurrence rate, the maintenance rate of sinus rhythm, the frequency of atrial fibrillation, the improvement of the ventricular rate.  Results:①A total of 11 systematic evaluations were included,and the median of the original studies included in the 11 literatures was 24. ②The overall methodological quality of the included system evaluations was extremely low,as assessed by the AMSTR 2 tool. The highest score of the 11 systematic evaluations by AMSTAR2 is 9,the lowest is 3.5,and the average score is 6.0. ③There were also some defects in the quality of the 11 systematic reports.The highest PRISMA score was 23.0,the lowest 15.0,and the average score was 19.8. ④Qualitative analysis showed that Wenxin granule combined with Western medicine was more effective and safer than Western medicine alone on cardioversion rate, recurrence rate and maintenance rate of sinus rhythm. But the clinical efficacy was limited in terms of ventricular rate and frequency of atrial fibrillation. In addition,due to the low quality of methodology included in the systematic evaluation and the low quality of relevant evidence,there may be variations in clinical use of the medicine.  Conclusion: The current evidence showed that Wenxin granule combined with Western medicine may have better effect for atrial fibrillation. However, at present, the methodological quality of the corresponding systematic evaluation is low, and the quality of the curative effect evidence is also low, the guiding value for clinical use of the medicine is limited. Therefore, it is suggested that Wenxin granule can only be used as an auxiliary drug for patients with non-valvular paroxysmal atrial fibrillation. It seems that more high quality and well-designed RCT are still needed to evaluate the efficacy and safety of Wenxin granule for atrial fibrillation.